PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.

Also called NCT04543812

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 141 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04543812
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04543812. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-14 (actual); primary completion 2022-10-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
Condition
Anemia of Chronic Kidney Disease
Intervention (Drug)
Ferric citrate
Intervention (Drug)
Placebo
Lead sponsor
Panion & BF Biotech Inc. (class: industry)

Record details

Record id
cardio:ct-nct04543812
Content hash
ced958c13362f04046f9d278ddd65532eb9d91dd9a63d26ba05fea4965a5daf3